U.S. measles cases surpass 5,000—the highest since the 1990s; could lift vaccine demand
Bloomberg reports U.S. measles cases have exceeded 5,000, the highest level since the 1990s.
View signal analysisCompany intelligence
GSK
GSK plc · NYSE · Healthcare
Price$50.45+0.52% · +$0.26
Market cap101.13BEquity value
P / E10.9Trailing ratio
Volume2.67MLatest session
Market data
TradingViewGSK price chart
Related signals
1 min delayedLatest GSK price-moving signals
Browse public GSK signals with their source context and measured market impact. Open any signal for its permanent analysis page.
GSK Q3 Beat Signals Growth Momentum Under Miels with Specialty Medicines
GlaxoSmithKline reported a third-quarter beat, helped by demand for specialty medicines. The results reinforce CEO Luke Miels' strategy to accelerate growth and position the company for upcoming launches, while keeping an eye on margins. Investors will monitor pipeline progress, competitive dynamics, and longer-term leverage as the company works toward its growth targets.
View signal analysisGSK-Hansoh bone cancer trial shows longer progression-free survival; potential upside
An experimental bone cancer therapy developed by Hansoh Pharmaceutical and GSK showed patients lived longer without disease worsening in early data presented at a medical meeting. The collaboration underscores GSK's oncology wing and Hansoh's development capabilities, potentially expanding licensing and co-commercial opportunities if further results confirm efficacy. The immediate impact hinges on how data translate into regulatory progress and partner economics.
View signal analysisGSK hepatitis B drug approved by FDA, potential near-term growth trigger
US FDA approval of GSK's hepatitis B drug marks a regulatory win and could shorten long-term therapy for patients. The catalyst may support near-term revenue and bolster confidence in GSK's pipeline, contingent on pricing, payer coverage, and uptake amid competition.
View signal analysisGSK to cut up to 1,217 Belgium jobs signaling European cost optimization
GSK plans to eliminate up to 1,217 Belgian roles, per L'Echo, signaling ongoing European cost optimization. The decision could influence near-term margins depending on severance and redeployment costs, while potentially boosting efficiency over time. Execution risk in the Belgian operation may weigh on near-term sentiment.
View signal analysisGSK to Invest $800 Million in PA Expansion Creating 300+ Jobs
GlaxoSmithKline will invest more than $800 million to expand its Upper Merion, PA site into a biopharmaceutical manufacturing and research hub, creating over 300 jobs in five years. The move expands GSK's U.S. manufacturing footprint and signals a longer-term push to scale biopharma capabilities, though no near-term earnings details were disclosed. The initiative could bolster pipeline manufacturing and supply resilience over time.
View signal analysisResearch